SurModics and EGEN Announce Collaboration
July  2010

EDEN PRAIRIE, Minnesota – July 12, 2010 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry and EGEN, Inc., a privately held biopharmaceutical company focused on developing nucleic acid (DNA and RNAi) therapeutics for the treatment of human diseases, are pleased to announce they have executed a continuation of their feasibility collaboration focused on long-term controlled release of siRNA complexes.
read full release

SurModics Showcases Drug Delivery Technology at The 37th Annual Meeting and Exposition of the Controlled Release Society
July  2010

EDEN PRAIRIE, Minnesota – July 09, 2010 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society (CRS), July 10-14, 2010 in Portland, Oregon (booth #521). SurModics announced that it is presenting four scientific posters on its drug delivery technologies ...
read full release

SurModics Signs License Agreement with Clinuvel Pharmaceuticals
July  2010

EDEN PRAIRIE, Minnesota – July 07, 2010 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders.
read full release

SurModics Receives ISO Certification at SurModics Pharmaceuticals Facilities
May  2010

EDEN PRAIRIE, Minnesota – May 19, 2010 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that its SurModics Pharmaceuticals facilities in Birmingham, Alabama have been certified by Det Norske Veritas (DNV) Certification, Inc. as compliant to the Quality Management System Standards ISO (International Standards Organization) 9001:2008 and ISO 13485:2003.
read full release

SurModics Opens World-class cGMP Facility for Manufacturing and Development in Birmingham, Alabama
January  2010

BIRMINGHAM, Alabama – January 21, 2010 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced that it has opened its new world-class facility for manufacturing and development in Birmingham, Alabama. The opening of this facility represents the culmination of events that began in April 2008 when SurModics announced the acquisition of a new building including office and warehouse space. Over the past 21 months, SurModics has made a significant infrastructure investment to build a new facility for parenteral and drug coated device products. 
read full release

Governor Riley Visits SurModics Pharmaceuticals to Encourage the Completion of a Science and Technology Roadmap for Alabama
September  2009

BIRMINGHAM, Alabama – September 22, 2009 – Governor Bob Riley spoke at SurModics Pharmaceuticals to support the collaboration of business, economic and academic leaders on building a roadmap for Alabama to reach its potential in science and technology.
read full release

James C. Greenwood to Give BAA Annual Meeting Keynote at SurModics Pharmaceuticals
May  2009

BIRMINGHAM, Alabama – May 4, 2009 – James C. Greenwood, President and CEO of the Biotechnology Industry Association (BIO), delivered the keynote address on the state of the Biotech Industry in these economic times at the Biotechnology Association of Alabama (BAA) Annual Meeting on May 4th, 2009 at SurModics Pharmaceuticals. Greenwood provided insights for strategic growth in the biotechnology industry in an increasingly competitive market.
read full release

Brookwood Pharmaceuticals is Now SurModics Pharmaceuticals
March  2009

EDEN PRAIRIE, Minnesota – March 16, 2009 – SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, has announced that Brookwood Pharmaceuticals, which SurModics acquired in July 2007 has been renamed SurModics Pharmaceuticals.
read full release

SurModics Acquires Drug Delivery Assets of
PR Pharmaceuticals
November  2008

EDEN PRAIRIE, Minnesota – November 4, 2008 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations. SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the successful achievement of certain milestones. The acquisition is expected to be accretive to SurModics’ fiscal 2009 earnings, excluding any one-time charges related to the acquisition.
read full release

SurModics License's Hex-PLA Drug Delivery System from the University of Geneva
October  2008

EDEN PRAIRIE, Minnesota – October 14, 2008 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery technologies and surface modification to the healthcare industry, announced today that its SurModics Pharmaceuticals, Inc. subsidiary has licensed Hex-PLA drug delivery technology from the University of Geneva. Under the agreement, SurModics has exclusive, worldwide rights to all pharmaceutical and drug delivery applications of the technology.
read full release

Alabama Governor Bob Riley visits
SurModics Pharmaceuticals
August  2008

BIRMINGHAM, Alabama – August 6, 2008 – Alabama Governor Bob Riley chose SurModics Pharmaceuticals as his Birmingham stop to mark Alabama’s being named the 2007 “State of the Year” in economic development by magazine Southern Business and Development. Riley chose SurModics because of its biotech connection. Art Tipton, president of SurModics Pharmaceuticals said the company plans to employ 300 employees within the next five years, up from around 80 today.
read full release

SurModics License's Nanotechnology Drug Delivery System
July  2008

EDEN PRAIRIE, Minnesota – July 14, 2008 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its SurModics Pharmaceuticals subsidiary has licensed lipid nanoparticle technology from PharmaSol GmbH of Berlin, Germany. Under the agreement, SurModics has exclusive rights to all pharmaceutical applications of the technology.
read full release

SurModics Purchases Additional Facility to Expand SurModics Pharmaceuticals’ Development and Manufacturing Capacity
April  2008

EDEN PRAIRIE, Minnesota – April 23, 2008 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that its SurModics Pharmaceuticals subsidiary, located in Birmingham, Alabama, has acquired an additional facility in the Birmingham area. This new facility will expand SurModics’ capacity for research and development activities and clinical manufacturing in support of customer projects. Additionally, the building will be SurModics’ corporate center for commercial GMP manufacturing of drug delivery products for pharmaceutical and biotechnology customers.
read full release

Tipton Inducted in the AIMBE College of Fellows
February  2008

Birmingham, Alabama – February 21, 2008 – Arthur J. Tipton, Ph.D., President, SurModics Pharmaceuticals, has been chosen as a new member of the College of Fellows by the American Institute for Medical and Biological Engineering (AIMBE). Tipton has been recognized for the development of biodegradable polymers and novel drug delivery systems. The induction ceremony is February 21, 2008.
read full release

SurModics Acquires Brookwood Pharmaceuticals: Strengthens Portfolio of Drug Delivery Technologies for the Pharmaceutical Industry
August  2007

EDEN PRAIRIE, Minnesota – August 1, 2007 – SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that it has acquired Brookwood Pharmaceuticals, Inc., a leading provider of drug delivery technology primarily to the pharmaceutical industry, from Southern Research Institute for $40 million in cash at closing and up to an additional $22 million in cash upon the successful achievement of specified milestones.
read full release

Carrington and SurModics Pharmaceuticals Expand GelSite® Drug Delivery Technology Development
July 2007

July 20, 2007 - Carrington Laboratories, Inc. today announced that its subsidiary, DelSite Biotechnologies, Inc., extended a joint development agreement with SurModics Pharmaceuticals, Inc. The goal of this effort is to continue an expanded evaluation of GelSite(R), a DelSite patented drug-delivery technology, as a matrix for injectable applications and for selected classes of drugs. This extension is built on the promising results and evaluations conducted by the joint technical team in the past year.
read full release

SurModics Pharmaceuticals, Targeted Technology Ventures Form New Company to Improve Cardiac Stents
May 2007

SurModics Pharmaceuticals, Inc. and Targeted Technology Ventures, LLC today announced the creation of a collaborative joint venture—Aeon Bioscience, Inc.—a company which will work to develop a new drug-eluting stent. The goal of the novel stent will be to overcome the current concerns of late stent thrombosis, or blood clot formation at or near the site of the stent and vessel closure due to formation of scar tissue, known as restenosis. SurModics Pharmaceuticals is a Birmingham-based drug-delivery company. Targeted Technology Ventures (TTV) is a San Antonio-based biotechnology and medical device company. Series A funding was secured through the Birmingham Technology Fund, managed by Greer Capital Advisors LLC of Birmingham. Aeon Bioscience will be headquartered in Birmingham.
read full release

elbion Acquires Late-Stage Product Candidate for Treatment of Alcohol Dependence 
January 2007

elbion NV, a leading European drug discovery and development company, today announced it has acquired a number of product candidates from the French biotechnology company DrugAbuse Sciences. The most advanced candidate, Naltrexone Depot, a sustained release formulation of naltrexone, will become elbion’s lead product and the company expects it to enter pivotal Phase III clinical trials in 2007. A second asset acquired is Buprenorphine Depot, a sustained release buprenorphine indicated for the treatment of opiate addiction. 
read full release

Lakeshore Biomaterials Announces New Polymer Products  
January 2007

BIRMINGHAM, ALABAMA– January, 2007 – Lakeshore Biomaterials announces a new catalog of polymer products with a simplified naming system.
more information

Secrist Named CEO of Southern Research Institute
September 2006

John A. “Jack” Secrist III, Ph.D. has been named president and CEO of Southern Research Institute following a national search, said UAB President and Southern Research Board chair Dr. Carol Z. Garrison. His appointment is effective Sept. 18. 
read full release

New Director of Quality 
August 2006

SurModics Pharmaceuticals welcomes Robert J. Brady as the Director of Quality.  “We are pleased to welcome Bob to our team,” says Arthur J. Tipton, PhD, CEO and President.  “He adds a wealth of experience and is a definite asset for the growing quality group at SurModics Pharmaceuticals”. 
read full release

Carrington and SurModics Pharmaceuticals Expand GelSite® Drug Delivery Technology Development
July 2006

July 20, 2006 - Carrington Laboratories, Inc. (NASDAQ:  CARN) announced today that its subsidiary, DelSite Biotechnologies, Inc., formed a joint development initiative with SurModics Pharmaceuticals, Inc.
read full release

Genzyme Pharmaceuticals and SurModics Pharmaceuticals Enter Broad Collaboration in Drug Delivery 
May 2006

May 1, 2006 - Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and SurModics Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions.
read full release

SurModics Pharmaceuticals, Scientific Advisory Board Convenes 
April 2006

April 25, 2006 - SurModics Pharmaceuticals' Scientific Advisory Board convened for the first time.
read full release

Lakeshore Biomaterials Names New Executives
May 2005

Lakeshore Biomaterials today named two new executives to its staff in Birmingham. Joining Lakeshore are Paul Spencer and John Middleton.
read full release

SRI Spins off drug group
January 2005

"They're going to have some dramatic opportunities for developing new pharmaceuticals and I can't think of a better way to get a company under way," said Mike Alder, director the Biotechnology Association of Alabama.
read full release.

SurModics Pharmaceuticals acquires the polymer business of Alkermes, Inc.
January 2005

Alkermes and Lakeshore Biomaterials are committed to produce a seamless transition of the polymer business, with the quality and service you've come to expect from the Alkermes Medisorb® polymer business.
read full release


Contact information:

SurModics Pharmaceuticals
756 Tom Martin Drive
Birmingham, AL 35211
phone 205.917.2200
fax 205.917.2205
Or visit our Contact Page.